Dutch-Swiss biotech startup Cradle has raised a $24 million in Series A funding. The company, which leverages the potential of generative AI for precise bioengineering, has convinced Index Ventures and Kindred Capital, as well as high-level angel investors, such as Tom Glocer, former CEO of Thomson Reuters and Lead Director of pharma giant Merck.
